Production (Stage)
Rani Therapeutics Holdings, Inc.
RANI
$0.556
$0.00150.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -12.92% | -6.28% | -15.19% | -11.08% | -5.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.18% | -8.65% | -33.92% | -31.54% | -15.03% |
| Operating Income | 14.40% | 16.30% | 33.92% | 31.54% | 15.03% |
| Income Before Tax | 13.81% | -11.86% | 30.60% | 28.41% | 12.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.81% | -11.86% | 30.60% | 28.41% | 12.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -24.97% | -2.62% | -34.99% | -29.96% | -13.76% |
| Net Income | 2.93% | -26.05% | 26.25% | 26.85% | 10.62% |
| EBIT | 14.40% | 16.30% | 33.92% | 31.54% | 15.03% |
| EBITDA | 14.68% | 16.88% | 34.57% | 32.23% | 15.57% |
| EPS Basic | 24.43% | 0.15% | 34.65% | 29.58% | 13.36% |
| Normalized Basic EPS | 0.27% | 68.27% | 23.21% | 24.97% | 8.58% |
| EPS Diluted | 24.43% | 0.15% | 34.65% | 29.58% | 13.36% |
| Normalized Diluted EPS | 0.27% | 68.27% | 23.21% | 24.97% | 8.58% |
| Average Basic Shares Outstanding | 28.45% | 26.23% | 12.85% | 3.86% | 3.15% |
| Average Diluted Shares Outstanding | 28.45% | 26.23% | 12.85% | 3.86% | 3.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |